Keywords: منطقه پسوریازیس و شاخص شدت; dose escalation; dose optimization; psoriasis; secukinumab; AE; adverse event; PASI; Psoriasis Area and Severity Index; PASI-75; 75% reduction from baseline PASI score; PGA; Physician Global Assessment;
مقالات ISI منطقه پسوریازیس و شاخص شدت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: منطقه پسوریازیس و شاخص شدت; ADA; anti-drug antibody; nADA; neutralizing anti-drug antibody; PASI; Psoriasis Area and Severity Index; PK; pharmacokinetics; Q2W; every 2 weeks; Q4W; every 4 weeks; TE-ADA; treatment-emergent anti-drug antibody;
Keywords: منطقه پسوریازیس و شاخص شدت; FCH; fold change; FDR; false discovery rate; GSVA; gene-set variation analysis; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; TH17; T helper type 17; TNF; tumor necrosis factor; TRANCE; tumor necrosis factor-related activation-induced cyto
Keywords: منطقه پسوریازیس و شاخص شدت; ISS; itch severity scale; NRS; numeric rating scale; PASI; Psoriasis Area and Severity Index; QoL; quality of life; VAS; visual analog scale;
Keywords: منطقه پسوریازیس و شاخص شدت; PASI; Psoriasis Area and Severity Index; IL; interleukin; fzd; frizzled receptors; IFN; interferon; ADAM; a disintegrin and metalloproteinase; EGF; epidermal growth factor; TGF; transforming growth factor; TPA; 12-o-tetradecanoyl phorbol-13-acetate; VEGF;
Keywords: منطقه پسوریازیس و شاخص شدت; enthesitis; nail; onycholysis; psoriatic arthritis; splinter hemorrhage; transverse grooves; CI; confidence interval; DIP; distal interphalangeal; NAPSI; Nail Psoriasis Severity Index; OR; odds ratio; PASI; Psoriasis Area and Severity Index; PsA; psoriati
Keywords: منطقه پسوریازیس و شاخص شدت; discontinuation; methotrexate; moderate-to-severe psoriasis; Psoriasis Area and Severity Index (PASI); prediction; response; AUC; area under the curve; DLQI; Dermatology Life Quality Index; ITT; intent-to-treat; PASI; Psoriasis Area and Severity Index; PA
Keywords: منطقه پسوریازیس و شاخص شدت; Psoriasis; Methotrexate; Dermatology life quality index; Psoriasis area and severity index;
Keywords: منطقه پسوریازیس و شاخص شدت; ACR; American College of Rheumatology; bDMARDs; biologic disease-modifying antirheumatic drugs; DMARDs; disease-modifying antirheumatic drugs; EULAR; European League Against Rheumatism; GRAPPA; Group for Research and Assessment of Psoriasis and Psoriatic
Keywords: منطقه پسوریازیس و شاخص شدت; AUC; area under the receiver operating characteristic curve; PASI; Psoriasis Area and Severity Index; PASI75; at least 75% reduction in Psoriasis Area and Severity Index score; UPSC; universal psoriasis skin classifier;
Keywords: منطقه پسوریازیس و شاخص شدت; Acitretin (PubChem CID:5284513); Methotrexate (PubChem CID:126941); DLQI; dermatology life quality index; ELISA; enzyme linked immunosorbent assay; IL; interleukin; PASI; psoriasis area and severity index; qRT-PCR; quantitative real-time polymerase chain
Keywords: منطقه پسوریازیس و شاخص شدت; CI; confidence interval; DLQI; dermatology life quality index; NMA; network meta-analysis; PASI; psoriasis area and severity index; RCT; randomized controlled trial; SUCRA; surface under the cumulative ranking curve;
Keywords: منطقه پسوریازیس و شاخص شدت; biological therapy; psoriasis; ustekinumab; ADA; antidrug antibodies; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index;
Keywords: منطقه پسوریازیس و شاخص شدت; apremilast; cost per responder; cost-effectiveness; indirect comparison; methotrexate; moderate to severe psoriasis; number needed to treat; Psoriasis Area and Severity Index; AAD; American Academy of Dermatology; CI; confidence interval; FDA; Food and Dr
Keywords: منطقه پسوریازیس و شاخص شدت; health state utility; psoriasis; Psoriasis Area and Severity Index; quality of life; time trade-off; willingness to pay;
Keywords: منطقه پسوریازیس و شاخص شدت; etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri
Keywords: منطقه پسوریازیس و شاخص شدت; Dermatology Life Quality Index; health-related quality of life; patient-reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment; DLQI; Dermatology Life Quality Index; HRQoL; h
Keywords: منطقه پسوریازیس و شاخص شدت; PASI; psoriasis area and severity index; AICAR; 5-aminoimidazole-4-carboxamide ribonucleotide; APCP; α,β-methylene adenosine-5â²-diphosphate; IL; interleukin; CVD; cardiovascular disease; DC; dendritic cell; Methotrexate; Psoriasis; Psoriatic arthritis
Keywords: منطقه پسوریازیس و شاخص شدت; Psoriasis; Inflammation; Obesity; n-3 Polyunsaturated fatty acids; n-6 Polyunsaturated fatty acids; Diet therapy; AA; arachidonic acid; AHA; American Heart Association; ALA; alpha-linolenic acid; DGLA; dihomo-gamma-linolenic acid; DHA; docosahexaenoic aci
Keywords: منطقه پسوریازیس و شاخص شدت; Dermatology Life Quality Index; patient-reported outcome; Physician Global Assessment; psoriasis; Psoriasis Area and Severity Index; quality of life; BSA; body surface area; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-rela
Keywords: منطقه پسوریازیس و شاخص شدت; Psoriasis; Comorbilidades; Criterios de gravedad: BSA; Body Surface Area; PASI; Psoriasis Area and Severity Index; DLQI; Dermatology Life Quality Index; Fototerapia; Retinoides; Metotrexato; Ciclosporina; Terapia biológica;
Keywords: منطقه پسوریازیس و شاخص شدت; chronic urticaria; diet; melanoma; nutrition; psoriasis; DLQI; Dermatology Life Quality Index; EGCG; epigallocatechin-3-gallate; IgE; immunoglobulin E; PASI; Psoriasis Area and Severity Index; PUFA; polyunsaturated omega-3 fatty acid; RCT; randomized, con
Keywords: منطقه پسوریازیس و شاخص شدت; Beau lines; epidemiology; leukonychia; nail psoriasis; Nail Psoriasis Severity Index; nails; onycholysis; psoriasis; splinter hemorrhages; NAPSI; Nail Psoriasis Severity Index; PASI; Psoriasis Area and Severity Index; PsA; psoriatic arthritis;
The expression of mCTLA-4 in skin lesion inversely correlates with the severity of psoriasis
Keywords: منطقه پسوریازیس و شاخص شدت; CTLA4; Cytotoxic T lymphocyte antigen-4; sCTLA-4; soluble Cytotoxic T lymphocyte antigen-4; mCTLA-4; membrane Cytotoxic T lymphocyte antigen-4; IOD; Integrated option density; IMQ; Imiquimod; PASI; psoriasis area and severity index; Treg; regulatory T; CT
Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways
Keywords: منطقه پسوریازیس و شاخص شدت; Resolvin D1; Keratinocyte; Psoriasis; Inflammation; MAPKs; Boc; tert-butoxycarbonyl Met-Leu-Phe peptide; GAPDH; glyceraldehyde-3-phosphate dehydrogenase; IL-17; interleukin-17; IL-22; interleukin-22; IL-23; interleukin-23; IMQ; imiquimod; MAPKs; mitogen-a
Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges
Keywords: منطقه پسوریازیس و شاخص شدت; ACR; American College of Rheumatology; ADAb; anti-drug antibody; ADCC; antibody-dependent cell-mediated cytotoxicity; AIFA; Italian Medicines Agency; CDC; complement-dependent cytotoxicity; CHMP; Committee for Medicinal Products for Human Use; DAS28; 28-j
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Keywords: منطقه پسوریازیس و شاخص شدت; AE; adverse event; BADBIR; British Association of Dermatologists Biologic Interventions Register; CI; confidence interval; HR; hazard ratio; PASI; Psoriasis Area and Severity Index; TNFI; tumor necrosis factor inhibitors;
Emerging therapies for atopic dermatitis: JAK inhibitors
Keywords: منطقه پسوریازیس و شاخص شدت; atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib; CPK; creatine phosphokinase; Cr; creatinine; EASI; Eczema Area and Severity Index; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; STAT; signal
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Keywords: منطقه پسوریازیس و شاخص شدت; cumulative benefit; itching; pain; psoriasis; quality of life; scaling; secukinumab; AUC; area under the curve; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-related quality of life; MCID; minimal clinically important differ
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Keywords: منطقه پسوریازیس و شاخص شدت; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPASI-1; CIMPASI-2; phase 3 trial; CZP; certolizumab pegol; DLQI; Dermatology Life Quality Index; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index;
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
Keywords: منطقه پسوریازیس و شاخص شدت; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPACT; etanercept; phase 3 trial; CZP; certolizumab pegol; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index; PASI 50; â¥50% reduction in PASI from
Myeloid but not plasmacytoid blood DCs possess Th1 polarizing and Th1/Th17 recruiting capacity in psoriasis
Keywords: منطقه پسوریازیس و شاخص شدت; mDCs/pDCs/DDCs; myeloid/plasmacytoid/dermal dendritic cells; IL; interleukin; IFNα; interferon alpha; TNFα; tumor necrosis factor alpha; iNOS; inducible nitric oxide synthase; PASI; Psoriasis Area and Severity index; PBMCs; peripheral blood mononuclear
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Keywords: منطقه پسوریازیس و شاخص شدت; clear or almost clear skin; clinical trial; phase 3; prospective; scalp psoriasis; secukinumab; Psoriasis Scalp Severity Index; AEs; adverse events; BSA; body surface area; CI; confidence interval; IGA mod 2011; Investigator's Global Assessment modified 2
Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris
Keywords: منطقه پسوریازیس و شاخص شدت; Tfh Cells; T follicular helper (Tfh) cells; PASI; psoriasis area and severity index; PV; psoriasis vulgaris; HC; healthy controls; SLE; systemic lupus erythaematosus; GC; germinal centre; PBMCs; peripheral blood mononuclear cells; PE; phycoerythrin; FITC;
Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity
Keywords: منطقه پسوریازیس و شاخص شدت; ApoE; apolipoprotein E; IMQ; imiquimod; TC; total cholesterol; TG; triglycerides; LDL; low density lipoproteins; HDL; high density lipoproteins; PASI; psoriasis area and severity index; PPARs; peroxisome proliferator activated receptors; IL; interleukin;
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Keywords: منطقه پسوریازیس و شاخص شدت; ABP 501; adalimumab; biosimilar; efficacy; equivalence; psoriasis; safety; ADA; antidrug antibody; CI; confidence interval; PASI; Psoriasis Area and Severity Index; PASI 50; 50% or more improvement in Psoriasis Area and Severity Index score from baseline;
Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease
Keywords: منطقه پسوریازیس و شاخص شدت; PBMC; peripheral blood mononuclear cells; TCM; central memory T cells; TEM; effector memory T cells; TEFF; effector T cells; PASI; Psoriasis Area and Severity Index; CRP; C-reactive protein; CLA; cutaneous lymphocyte-associated antigen; Th1; T helper 1 ce
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-
Keywords: منطقه پسوریازیس و شاخص شدت; adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Â year: Results from the CLEAR study
Keywords: منطقه پسوریازیس و شاخص شدت; psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As
Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis
Keywords: منطقه پسوریازیس و شاخص شدت; aTreg; activated regulatory T cells; Foxp3; forkhead-box p3; IL; interleukin; non-Treg; non-suppressive regulatory T cells; PASI; Psoriasis Area and Severity Index; PUVA; psoralen plus ultraviolet light A; rTreg; resting regulatory T cells; Th17; interleu
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Keywords: منطقه پسوریازیس و شاخص شدت; itch; itch numeric rating scale; patient-reported outcomes; psoriasis; skin appearance bothersomeness; skin pain; HRQoL; health-related quality of life; NRS; numeric rating scale; PASI; Psoriasis Area and Severity Index; PRO; patient-reported outcome; PSA
Hypermethylation of HLA-C may be an epigenetic marker in psoriasis
Keywords: منطقه پسوریازیس و شاخص شدت; HLA; human leukocyte antigen class; PASI; psoriasis area and severity index; PBMCs; blood mononuclear cells; PP; psoriatic lesion; PN; psoriatic non-lesion; NN; normal skin; KIRs; killer immunoglobulin-like receptors; Psoriasis; HLA; Gene methylation; mRN
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical
Keywords: منطقه پسوریازیس و شاخص شدت; apremilast; difficult to treat; ESTEEM; moderate to severe; palmoplantar psoriasis; palms; PSOR-005; soles; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; IL; interleukin; m-PPPASI; modified Palmoplantar Psoriasis Are
HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series
Keywords: منطقه پسوریازیس و شاخص شدت; chronic plaque psoriasis; HLA-Cw*0602; Psoriasis Disability Index; Psoriasis Life Stress Inventory; sore throat; streptococcal throat infection; tonsillectomy; PASI; Psoriasis Area and Severity Index; PDI; Psoriasis Disability Index; PLSI; Psoriasis Life
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
Keywords: منطقه پسوریازیس و شاخص شدت; apremilast; nail psoriasis; phosphodiesterase 4 inhibitor; psoriasis; scalp psoriasis; systemic therapy; BID; twice daily; ESTEEM; Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; NAPSI; Nail Psoriasis Severity Index; NAPSI-50;
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
Keywords: منطقه پسوریازیس و شاخص شدت; efficacy; Janus kinase inhibitor; long-term; psoriasis; randomized controlled trial; safety; tofacitinib; AE; adverse event; BID; twice daily; CI; confidence interval; HZ; herpes zoster; IR; incidence rate; LTE; long-term extension; NMSC; nonmelanoma skin
ReviewSystematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent
Keywords: منطقه پسوریازیس و شاخص شدت; adalimumab; etanercept; failure; infliximab; psoriasis; switching; tumor necrosis factor antagonist; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index; PASI50; 50% improvement in Psoriasis Area and Severity Index score; PASI75;
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes
Keywords: منطقه پسوریازیس و شاخص شدت; CTLA4; cytotoxic T-lymphocyte-associated protein 4; DEG; differentially expressed gene; FDR; false discovery rate; GSVA; gene set variation analysis; K16; keratin 16; PASI; Psoriasis Area and Severity Index; TH; T helper; Treg; regulator T cell;
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets
Keywords: منطقه پسوریازیس و شاخص شدت; CTLA4; cytotoxic T lymphocyte-associated protein 4; FoxP3; forkhead box P3; PASI; psoriasis area and severity index; TNF; tumor necrosis factor; Treg; regulatory T cell;
HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program
Keywords: منطقه پسوریازیس و شاخص شدت; HLA; human leukocyte antigen; HLA-C*06:02-POS; HLA-C*06:02-positive; HLA-C*06:02-NEG; HLA-C*06:02-negative; PASI; Psoriasis Area and Severity Index; PASI 50/75/70; 50/75/90% improvement from baseline in Psoriasis Area and Severity Index; TNF; tumor necros